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http://www.lipidworld.com/content/12/1/83RESEARCH Open AccessLoss of fatty acid synthase inhibits the “HER2-PI3K/
Akt axis” activity and malignant phenotype of
Caco-2 cells
Nan Li1*, Heng Lu1, Chunyan Chen1, Xiaodong Bu2 and Peilin Huang2*Abstract
Background: Fatty acid synthase (FASN) is frequently activated and overexpressed in human cancers, and plays a
crucial role in the carcinogenesis of various cancers. In this study, our aims were to explore the role of FASN in
regulating the “HER2-PI3K/Akt axis” activity and malignant phenotype of colorectal cancer.
Methods: Caco-2 cells with a high expression of both HER2 and FASN were selected for functional characterization.
Caco-2 cells were transfected with either the FASN specific RNAi plasmid or the negative control RNAi plasmid,
followed by the RT-qPCR and western blot to examine the expression of FASN, HER2, PI3K and Akt. The MTT and
colony formation assays were used to assess the proliferation potential. The migration was investigated by the
transwell, and the apoptosis and cell cycle were assayed by the flow cytometry.
Results: Notably, the expression of FASN, HER2, PI3K and Akt were downregulated upon a silence of FASN. The
proliferation was decreased after a downregulation of FASN, which was consistent with an increased apoptosis rate.
The migration was also impaired in FASN-silenced cells.
Conclusion: A downregulation of FASN effectively inhibits the activity of “HER2-PI3K/Akt axis” and alters the
malignant phenotype in colorectal cancer cells.
Keywords: FASN, “HER2-PI3K/Akt axis”, Malignant phenotype, Caco-2 cellsBackground
Fatty acid synthase (FASN) is a homodimeric multi-
enzymatic protein which can be divided into seven func-
tional domains that are assembled into two homodimers
[1]. Through a series of reactions, FASN synthesizes the
long chain fatty acids (LCFA) using acetyl-CoA and
malonyl-CoA as substrates and NADPH as an electron
donor, respectively [2]. FASN is expressed by the lipogenic
tissues, hormone-sensitive cells and proliferating fetal cells
[3]. In normal cells, FASN expression maintains at a low
level and its regulation is a complex process highly relying
on the nutritional status and hormonal profile [4,5]. How-
ever, in cancer cells and pre-neoplastic lesions, FASN
expression has been frequently found to be upregulated.* Correspondence: linan0627@yahoo.cn; hplwpp@yahoo.cn
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reproduction in any medium, provided the orAn increased FASN expression is associated with the
cancer progression, higher risk of recurrence and shorter
survival in many types of cancers [6-8].
An increased FASN expression renders cancer cells no
longer responsive to the nutritional cue [9]. Though there
are many potential causes for its upregulation, the tran-
scriptional regulation of FASN expression has been con-
sidered to be the major cause for the increased FASN
expression in cancer cells [10-12]. It has been shown that
the growth factors, hormones and activation of their re-
ceptors increased FASN transcription in cancer cells. For
example, epidermal growth factor (EGF) can stimulate
FASN expression through the EGF receptor ERBB1 and
ERBB2 (HER2; Her-2/neu) [10,11]. Furthermore, the effect
of growth factors, hormones and their receptors on FASN
expression involves a complicated downstream signaling
and crosstalk between multiple signal transduction path-
ways. A well-studied major pathway that is possibly in-
volved in regulating FASN expression is the PI3K/Akthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the link between the PI3K/Akt activity and FASN ex-
pression [13,14].
A transcriptome analysis of HER2 in breast cancer
cells has revealed a molecular connection between FASN
and HER2 through the PI3K/Akt pathway [10]. In this
study, the authors used DNA microarray to compare
and identify genes induced by HER2 in mammary epi-
thelial cell line with ectopic HER2 overexpression and
breast cancer cell lines derived from patients with differ-
ent level of HER2 expression. They found that HER2
overexpression activated FASN promoter and transcrip-
tion as well as increased protein production and activity,
while inhibitors of HER2, Herceptin and CI-1003, at-
tenuated the effect of HER2 on FASN expression. PI3K
activity was thought to be the mediator of the HER2
control on FASN expression because LY294002, a
known PI3K inhibitor, abrogated HER2 induced FASN
protein production in the HER2 overexpressing normal
mammary epithelial and breast cancer cells. Thus, the
transcription of FASN gene may be induced by HER2 via
the PI3K/Akt pathway. Conversely, FASN dependent regu-
lation of HER2 expression has also been reported [15].
Hence, in this study, we analyzed the potential link be-
tween FASN and the activity of “HER2-PI3K/Akt axis”
in colorectal cancer cells. And the influence of FASN on
proliferation and migration of colorectal cancer cells was
also explored.
Materials and methods
Cell culture and selection
Four human colorectal cancer cells of Caco-2, HT-29,
LoVo and LS174T were used in this study. All cells were
purchased from Shanghai Cell Biology Institute of Chinese
Academy of Sciences (Shanghai, China). HT-29, LoVo
and LS174T cells were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum (Invitrogen,
USA). Caco-2 cells were cultured in minimum essential











Reverse cctgAAATGTACTserum (Invitrogen, USA). All cells were incubated at 37°C
in a humidified atmosphere supplemented with 5% CO2.
HER2 and FASN mRNA expression of four cells were
detected by the RT-qPCR. A negative control RNAi plas-
mid with the scrambled sequences (marked as MR-Neg)
(Table 1) was synthesized according to the manufacturer’s
instructions (Invitrogen, USA), and four cells were transi-
ently transfected with the MR-Neg to detect the transfec-
tion efficiency. HER2 and FASN mRNA expression and
the transfection efficiency of four cells were integrated for
selecting target cells.
Plasmid construction and stable transfectional cells
establishment
Knockdown of FASN was achieved with an RNA inter-
ference approach using microRNA to obtain the stable
clones. Four different FASN specific RNAi plasmids
(marked as MR-FASN-1—MR-FASN-4) were synthesized
according to the manufacturer’s instructions (Invitrogen,
USA) (Table 1), and Caco-2 cells were transiently trans-
fected with them, respectively. FASN mRNA expression
was detected by the RT-qPCR to validate knockdown
effect and choose the most effective FASN specific RNAi
plasmid. Then Caco-2 cells were respectively transfected
with the most effective FASN specific RNAi plasmid
(MR-FASN-2) and the negative control RNAi plasmid
(MR-Neg) using Lipofectamine 2000 according to the
Invitrogen technical bulletin. Blasticidin (7 μg/ml) was
used to select for the stable clones.
Real-time quantitative polymerase chain reaction
Total RNA was isolated with the TRIzol method
(Invitrogen, USA). cDNA was synthesized by a reverse
transcription system kit (Invitrogen, USA) according to
the manufacturer’s instruction. Gene mRNA expression
was verified using a fluorescence quantitative PCR system
(BioRad, USA). Glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) was used as an internal standard. The












Table 2 The gene primer sequences
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at 95°C for 2 min, followed by 40 amplification cycles of
95°C for 10 s, 60°C for 30 s, and 70°C for 45 s. Every
real-time PCR assay contained 1.2 μl cDNA template,
0.5 μl SYBR green, and 0.5 μl of every forward and reverseFigure 1 Cell selection. (A) HER2 and FASN mRNA expression of Caco-2,
P < 0.05; Compared with LS174T cells, P > 0.05. & Compared with HT-29, LoV
specific RNAi plasmids and the negative control RNAi plasmid. (C) The whi
LS174T cells transiently transfected with the negative control RNAi plasmidprimer in a 25 μl reaction mixture. Relative gene mRNA
expression was analyzed using the 2-ΔΔCT method [16].Western blot analysis
Equal amounts of protein (100 μg per lane) were
subjected to a 4%-12% NuPAGE Novex Bis-Tris Mini
Gels (Invitrogen, USA) and the separated proteins were
transferred onto the Immobilon P PVDF membrane
(Invitrogen, USA). The membranes were blotted using
primary antibodies directed against human FASN (1:500,
Cell Signaling Technology, USA), HER2, PI3K, Akt and
phosphAkt (1:500, Signalway Antibody, USA). After in-
cubation with the appropriate antirabbit or antimouse
horseradish peroxidase-conjugated secondary antibody
(1:10000, Santa Cruz, CA), immunoreactive bands were
visualized by the chemiluminescence dissolvent and
exposured to the X-ray film. GAPDH (1:10000, Santa Cruz,
CA) protein expression was used as a normalization
control for protein loading.HT-29, LoVo and LS174T cells. * Compared with HT-29 and LoVo cells,
o and LS174T cells, P < 0.05. (B) The sequencing of four different FASN
te light and fluorescent photographs of Caco-2, HT-29, LoVo and
for 24 h (×100 magnification).
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Cells (6 × 103/200 μl/well) were seeded in 96-well plates.
Viable proliferating cells were detected by the 3-(4,-
dimethy-lthiazol-2-yl)-2,-diphenyl-tetrazoliumbromide
(MTT) assay at various time period (24, 48, 72, 96, and
120 h), using six wells per time period. Cell viability was
expressed as optical density (OD), which was detected
by an enzyme-linked immunoabsorbent assay reader
(Thermo, MK3, USA) at 492 nm wavelength.Colony formation assay
Cells (6 × 102/2 ml/well) were seeded in 6-well plates,
and cultured for 2 weeks to form colonies. The formed
colonies were stained with Giemsa, and the coloniesFigure 2 Plasmid selection. (A) The white light and fluorescent photogra
with four different FASN specific RNAi plasmids and the negative control R
of Caco-2 cells transiently transfected with four different FASN specific RNAi p
with other groups, P < 0.05.containing more than 50 cells were counted under an
inverted microscope.Cell migration assay
Cell migration was measured in 24-well plates by the
transwell assay using a chamber containing the polyethylene
terephthalate filter membrane with 8-μm pores (Corning,
USA). Cells (6 × 104/200 μl/chamber) were seeded in the
upper chamber with MEM, and 500 μl MEM supplemented
with 10% fetal bovine serum was filled in the lower well as
a chemoattractant. After incubation for 24 h, the cham-
bers were stained with hematoxylin-eosin (HE). The mi-
grated cells were counted from five randomly selected
fields under an inverted microscope.phs of transfection efficiency of Caco-2 cells transiently transfected
NAi plasmid for 24 h (×100 magnification). (B) FASN mRNA expression
lasmids and the negative control RNAi plasmid for 24 h. * Compared
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Cells (5 × 105) were harvested, washed with PBS and
resuspended in Binding Buffer (Kaijibio, China), followed
by mixing with Annexin V-FITC and Propidium iodide
(Kaijibio, China). Cells were analyzed by a Becton-Dickinson
FACSCalibur flow-cytometer provided with the CellQuest
software (Braintree, MA).
Cell cycle analysis
Cells (1 × 106) were harvested, washed with PBS and fixed
in 70% ethanol. The fixed cells were washed with PBS and
resuspended in RNase A (Kaijibio, China), followed by
incubation at 37°C for 30 min. Cells were stained with
PI solution (Kaijibio, China) and analyzed by a Becton-
Dickinson FACSCalibur flow-cytometer provided with
the CellQuest software (Braintree, MA).
Statistical analysis
Statistical comparisons were performed by SAS software,
version 9.1 (SAS Institute, Cary, NC). Values are presented
as means ± standard error of mean (SEM). The statistical
significance of differences was determined by One-way
ANOVA with a post-hoc test (Student-Newman-KeulsFigure 3 FASN, HER2, PI3K and Akt expression of Caco-2 cells by RNA in




HER2 mRNA expression of Caco-2, HT-29, LoVo and
LS174T cells were respectively 138.46 ± 77.6, 365.4 ± 113.48,
1.00 and 137.19 ± 51.32. FASN mRNA expression of them
were respectively 70.52 ± 11.53, 22.21 ± 6.41, 92.63 ± 0.98
and 1.00 (Figure 1A). After transiently transfected with
the MR-Neg for 24 h (Figure 1B), the transfection effi-
ciency of four cells was investigated by an inverted fluor-
escence microscope (Figure 1C). Caco-2 cells were the
only cell line tested that expressed reasonable levels of
both HER2 and FASN and had good plasmid uptake.
Hence, Caco-2 cells were selected as the target cells to
perform further experiments.
Plasmid selection and stable transfectional cells
establishment
Upon the transient transfection of four different FASN
specific RNAi plasmids for 24 h (Figure 2A), the FASN
mRNA expression of Caco-2 cells was 1.64 ± 0.72,terference. (A) FASN, HER2, PI3K and Akt mRNA expression. * Compared
t protein expression.
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other groups, FASN mRNA expression of Caco-2 cells
transfected with the MR-FASN-2 was the lowest (P < 0.05)
(Figure 2B). Therefore, Caco-2 cells were transfected
with the most effective FASN specific RNAi plasmid
(MR-FASN-2) and the negative control RNAi plasmid
(MR-Neg), and blasticidin (7 μg/ml) was used to select
for stable clones.Inhibition of FASN by RNA interference suppressed the
activity of “HER2-PI3K/Akt axis” in Caco-2 cells
FASN mRNA expression of experimental group was 0.17 ±
0.07, significantly lower than the control groups (0.72 ±
0.22 and 1.00) (P < 0.05) (Figure 3A). FASN protein expres-
sion was also decreased, compared to two control groups
(Figure 3B). Interestingly, after inhibiting FASN expres-
sion, HER2, PI3K and Akt mRNA expression of FASN-
RNAi group were 0.45 ± 0.11, 0.15 ± 0.01 and 0.42 ± 0.06,
all significantly lower than the control groups (0.69 ±
0.07 and 1.00, 0.49 ± 0.13 and 1.00, 0.86 ± 0.03 and 1.00)
(P < 0.05) (Figure 3A). Correspondingly, HER2, PI3K and
Akt protein expression were also dramatically declined
(Figure 3B). In addition, western blot analysis showed a
significant decrease in phosphAkt, as well (Figure 3B).Figure 4 The proliferation and migration of Caco-2 cells by RNA inter
groups, P < 0.05. (B) The colony formation Rate. * Compared with two cont
two control groups, P < 0.05 (HE, ×200 magnification).Inhibition of FASN blocked proliferation and migration of
Caco-2 cells
To examine the possible involvement of FASN in cancer
progression, the proliferation and migration of Caco-2
cells after silencing FASN were assessed using the
MTT, colony formation and transwell assays. As shown
in Figure 4A, the OD values measured at 5 days showed
that the proliferation of experimental group was sig-
nificantly lower than two control groups (P < 0.05). The
colony formation rate of FASN-silencing group was
3.45% ± 0.003, and was obviously declined, compared
with the blank control group (11.33 % ± 0.02) and nega-
tive control group (11.78% ± 0.02) (P < 0.05) (Figure 4B).
In the transwell assay, FASN silenced cells migrated
less efficiently than control cells (P < 0.05) (Figure 4C).
The number of migrating FASN silenced Caco-2 cells
was 129 ± 4.36, compared with 295.33 ± 4.04 in the
blank control group and 327 ± 14.53 in the negative
control group.RNA interference induced apoptosis of Caco-2 cells
Meanwhile, FASN silence led to a higher early apoptosis
rate (75.57% ± 0.05) in Caco-2 cells (P < 0.05) (Figure 5A).
Rather, there was no difference in the late apoptosis rateference. (A) The proliferation curve. Compared with two control
rol groups, P < 0.05. (C) The migration cell number. * Compared with
Figure 5 The apoptosis and cell cycle of Caco-2 cells by RNA interference. (A) The apoptosis rate. * Compared with two control groups,
P < 0.05. & Compared with two control groups, P > 0.05. (B) The cell cycle percentage. * Compared with two control groups, P > 0.05.
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2.83% ± 0.01 and 2.53% ± 0.01) (P > 0.05) (Figure 5A).
Additionally, no significant changes in cell cycle were
observed upon FASN silence (P > 0.05) (Figure 5B).
Discussion
Altered metabolism in human cancers has long been
recognized. Endogenous fatty acid biogenesis catalyzed
by the lipogenic enzymes such as FASN constitutes an
oncogenic stimulus that drives the normal epithelial cells
progression toward malignancy [17,18]. Intriguingly, re-
cent experimental evidence supports the notion that
the oncogenic nature of FASN-associated lipogenesis
closely depends on the activity and expression of key
cancer-related oncogenes such as HER2 [19,20]. HER2
overexpression leads to constitutive upregulation and
maintenance of an exacerbated FASN-catalyzed endogenous
fatty acid biogenesis [21,22], a “lipogenic benefit” in terms of
enhanced cell proliferation, survival, chemoresistance and
metastasis [14,23]. Conversely, disturbance of the lipogenicphenotype rapidly switches-off the oncogenic activity of
the HER2 signaling platform, ultimately resulting in
apoptotic tumor cell death [24,25]. Furthermore, the
sole activation of endogenous fatty acid biosynthesis in
non-cancerous epithelial cells is sufficient to induce a
cancer-like phenotype functionally dependent on HER2
activity [20]. These findings reveal that HER2 oncogene
establishes a positive bidirectional relationship with
FASN, in this way strictly ensuring a hyperactive de
novo fatty acid biogenesis.
In the current study, we demonstrated that RNAi-
mediated inhibition of FASN dramatically reduced the
expression of HER2, PI3K and Akt in colorectal cancer
cells. It implies that FASN can effectively regulate the
“HER2-PI3K/Akt axis” activity of colorectal cancer cells.
Considering that HER2 overexpression stimulates the
activity of FASN and ultimately mediates increased en-
dogenous fatty acid biosynthesis [10,26], these findings
implies a bidirectional connection between FASN and
HER2 in colorectal cancer cells. Additionally, it also
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signaling pathways regulating proliferation, metabolism
and survival in colorectal cancer cells, but also controls
genes inducing malignant transformation in colorectal
oncogenesis.
Recent evidences indicate that cancers with high ex-
pression of FASN always undergo a significant endogen-
ous fatty acid biosynthesis and display a biologically
aggressive subset [27,28]. Moreover, the upregulation of
FASN expression is an early event in cancer develop-
ment [29], it is more pronounced in advanced tumors,
and correlates with a poor prognosis [27]. Importantly,
we and others have demonstrated that inhibition of
FASN with pharmacological inhibitors is selectively cyto-
toxic to human cancer cells and leads to a significant
antitumor effect [30,31], suggesting that activation of
fatty acid synthesis is required for carcinogenesis.
In this study, we observed that RNAi of FASN expres-
sion blocked the proliferation and migration of colorectal
cancer cells and increased apoptosis rate. Furthermore,
the decreased proliferation and migration of colorectal
cancer cells could be partly attributed to the decreased ac-
tivity of “HER2-PI3K/Akt axis” what was regulated by
FASN. It implies that FASN plays a central role in the
malignant phenotype maintenance of colorectal cancer
cells by enhancing cancer cell survival and proliferation.
All these findings suggest that FASN may be used for
diagnosis, prognosis, early intervention, and treatment
of various human cancers. However, further studies
would be necessary to understand the role of FASN in
the carcinogenesis.
As a large protein with a complex structure and multiple
catalytic domains, FASN is considered as an important
metabolic enzyme and a potential target in human cancers.
Elevated FASN expression appears to be an early event in
the tumorigenesis, and it is regulated by several signaling
pathways. Elevated FASN expression in cancer cells seems
to modulate lipid raft domains and various biological pro-
cesses which in turn prevent apoptosis and promote cell
survival. However, the detailed mechanism on how FASN
regulates these biological processes is currently unknown.
Although it is now known that FASN may be a proto-
oncogene and its overexpression promotes tumorigenesis
and survival, how FASN is upregulated in normal or pre-
neoplastic cells to promote tumorigenesis is unclear, which
requires and deserves further investigation.Competing interests
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